Filing Flows › Axsome Therapeutics (AXSM) › Q2 2026 › vs Q1 2026
Axsome Therapeutics (AXSM) Q2 2026 vs Q1 2026 (quarter over quarter)
Axsome Therapeutics's revenue rose $27.2M (+14%) from $191M in Q1 2026 to $218M in Q2 2026. The biggest changes: Product +$27.0M (+14%); Royalty and Milestone Revenue +$217K (+12%).
Axsome Therapeutics, Q2 2026: revenue $218M (+46% year over year), operating margin -22.7%, net loss $51.3M, operating cash flow −$33.0M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product | $216M | $189M | $27.0M | +14% |
| Royalty and Milestone Revenue | $2.0M | $1.8M | $217K | +12% |
| Revenue | $218M | $191M | $27.2M | +14% |
| Net loss | $51.3M | $64.5M | −$13.2M | -20% |
| Costs & expenses | $270M | $256M | $13.9M | +5% |
| Operating costs | $268M | $255M | $13.5M | +5% |
| Interest & other, net | $1.5M | $1.2M | $355K | +30% |
| Income tax | $128K | $0 | $128K | — |
| Cost of revenue | $13.6M | $14.7M | −$1.2M | -8% |
| Research & development | $46.2M | $52.7M | −$6.5M | -12% |
| SG&A | $208M | $185M | $23.1M | +13% |
| Operating cash sources | $61.8M | $45.8M | $16.0M | +35% |
| Depreciation & amortization | $1.7M | $1.7M | $44K | +3% |
| Share-based compensation | $27.1M | $23.4M | $3.7M | +16% |
| Cash used in operations | $33.0M | $20.7M | $12.3M | +59% |
| Net loss absorbed | $51.3M | $64.5M | −$13.2M | -20% |
| Working capital & other | $10.5M | −$18.7M | $29.2M | — |
Questions
How much did Axsome Therapeutics's revenue grow quarter over quarter in Q2 2026?
Axsome Therapeutics's revenue rose $27.2M (+14%) from $191M in Q1 2026 to $218M in Q2 2026.
What drove Axsome Therapeutics's revenue change in Q2 2026?
Product +$27.0M (+14%); Royalty and Milestone Revenue +$217K (+12%).